免疫精准扩大2022财年第二季度净亏损同比

08:48 AM EST, 12/13/2021 (MT Newswires) -- ImmunoPrecise Antibodies Ltd. (IPA.V), a player in full-service therapeutic antibody discovery and development that at last look fell 1.4% in US pre-market trading, on Monday reported net loss of $5.0 million for the second quarter of fiscal year 2022, widening from a net loss of $463,584 in the year-ago quarter.

Revenues for the quarter amounted to $4.7 million, a 0.7% decrease from the same period last year. Complications from travel restrictions due to COVID-19 impacting implementation of a new ERP system, along with associated new processes and procedures, caused the company to miscalculate eliminations of intercompany transactions during the first three quarters of fiscal year 2021, primarily related to internal research and development sales to its subsidiary Talem Therapeutics LLC.

The miscalculation resulted in immaterial but notable variances in revenues for the first three quarters of fiscal year 2021. Taking into account the prior-year miscalculation, total revenues for the three months ended Oct. 31 would have reflected a 15.5% increase year over year.

Adjusted EBITDA was a loss of $2.9 million, down from positive EBITDA of $795,159 in the year-ago quarter.

The company, primarily through Talem, invested $2.8 million in strategic research and development costs, an increase from $1.1 million in the same period a year ago.